PatentsGlobal
Moleculin Expands Annamycin Patent Rights with New Approval in South Korea
Moleculin has strengthened its global intellectual property holdings by obtaining a patent allowance for Annamycin in South Korea. This development marks a significant step in the company’s efforts to protect and commercialize its innovative oncology drug worldwide.
Wednesday, November 18, 2026